Eye on ESMO 2016
The largest dedicated oncology conference in Europe, ESMO 2016, takes place 7-11 October.
pharmaphorum was onsite and in conjunction with Kantar Health provided exclusive daily insights from the event, delivering highlights and analysis of the key papers.
Oncology firm could make acquisition if ovarian cancer drug approved.
Roche’s PD-L1 drug has generated impressive data in second line lung cancer
Despite Keytruda’s overwhelming victory, it’s not over yet in NSCLC
But BMS dumps combination with Yervoy.
Merck unveils impressive data on Keytruda, trumping BMS’ Opdivo
Commentary on key cancer data from ESMO by Stephanie Hawthorne
Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise
Europe’s biggest cancer conference ESMO is underway
New immunotherapies are producing impressive results in lung cancer